Circulation Research. 2003;93:280-291
doi: 10.1161/01.RES.0000087541.15600.2B
doi: 10.1161/01.RES.0000087541.15600.2B
© 2003 American Heart Association, Inc.
Reviews |
Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function
From the Departments of Pharmacology (S.D.R., J.A.B.) and Pathology (K.E.B.), University of Washington School of Medicine, Seattle, Wash; and the Center for Cardiovascular Research (C.Y.), University of Rochester, Rochester, NY.
Correspondence to J.A. Beavo, Department of Pharmacology, Box 357280, University of Washington, Seattle, WA 98195. E-mail beavo{at}u.washington.edu
Cyclic GMP (cGMP) made in response to atrial natriuretic peptide (ANP) or nitric oxide (NO) is an important regulator of short-term changes in smooth muscle tone and longer-term responses to chronic drug treatment or proliferative signals. The ability of smooth muscle cells (SMCs) to utilize different combinations of phosphodiesterase (PDE) isozymes allows cGMP to mediate these multiple processes. For example, PDE5 as a major cGMP-hydrolyzing PDE effectively controls the development of smooth muscle relaxation. In order for contraction to occur, PDE5 is activated and cGMP falls. Conversely, blockade of PDE5 activity allows the relaxation cycle to be prolonged and enhanced. A recently shown direct activation of PDE5 by cGMP binding to the GAF A domain suggests that this regulatory site might be a target for new drug development. The calcium surge associated with vasoconstrictor initiated contraction also activates a calcium/calmodulin-dependent PDE (PDE1A). Together, PDE5 and PDE1A lower cGMP sufficiently to allow contraction. Longer term, both PDE5 and PDE1A mRNA are induced by chronic stimulation of guanylyl cyclase. This induction is a major cause of the tolerance that develops to NO-releasing drugs. Finally, high levels of cGMP or cAMP also act as a brake to attenuate the proliferative response of SMCs to many mitogens. After vessel damage, in order for SMC proliferation to occur, the levels of cGMP and cAMP must be decreased. In humans, this decrease is caused in large part by induction of another Ca2+/calmodulin-dependent PDE (PDE1C) that allows the brake to be released and proliferation to start.
Key Words: cyclic GMP • smooth muscle function
This article has been cited by other articles:
 |
|
 |
|
  R. L. Neppl, L. T. Lubomirov, K. Momotani, G. Pfitzer, M. Eto, and A. V. Somlyo Thromboxane A2-induced Bi-directional Regulation of Cerebral Arterial Tone J. Biol. Chem., March 6, 2009; 284(10): 6348 - 6360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tradtrantip, B. Yangthara, P. Padmawar, C. Morrison, and A. S. Verkman Thiophenecarboxylate Suppressor of Cyclic Nucleotides Discovered in a Small-Molecule Screen Blocks Toxin-Induced Intestinal Fluid Secretion Mol. Pharmacol., January 1, 2009; 75(1): 134 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hofbauer, A. Schultz, and J. E. Schultz Functional Chimeras of the Phosphodiesterase 5 and 10 Tandem GAF Domains J. Biol. Chem., September 12, 2008; 283(37): 25164 - 25170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Heikaus, J. R. Stout, M. R. Sekharan, C. M. Eakin, P. Rajagopal, P. S. Brzovic, J. A. Beavo, and R. E. Klevit Solution Structure of the cGMP Binding GAF Domain from Phosphodiesterase 5: INSIGHTS INTO NUCLEOTIDE SPECIFICITY, DIMERIZATION, AND cGMP-DEPENDENT CONFORMATIONAL CHANGE J. Biol. Chem., August 15, 2008; 283(33): 22749 - 22759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-C. Peyter, V. Muehlethaler, L. Liaudet, M. Marino, S. Di Bernardo, G. Diaceri, and J.-F. Tolsa Muscarinic receptor M1 and phosphodiesterase 1 are key determinants in pulmonary vascular dysfunction following perinatal hypoxia in mice Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L201 - L213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Urdaneta, E. Lobato, T Beaver, J. Muehlschlegel, D. Kirby, C Klodell, and A Sidi Treating pulmonary hypertension post cardiopulmonary bypass in pigs: milrinone vs. sildenafil analog Perfusion, March 1, 2008; 23(2): 117 - 125. [Abstract] [PDF]
|
|
|
|
 |
|
 A. L. Burnett Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health J Androl, January 1, 2008; 29(1): 3 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass, H. C. Champion, and J. A. Beavo Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation Circ. Res., November 26, 2007; 101(11): 1084 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Xia, C. Dimitropoulou, J. Zeng, G. N. Antonova, C. Snead, R. C. Venema, D. Fulton, S. Qian, C. Patterson, A. Papapetropoulos, et al. Chaperone-dependent E3 ligase CHIP ubiquitinates and mediates proteasomal degradation of soluble guanylyl cyclase Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3080 - H3087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Coggins and K. D. Bloch Nitric Oxide in the Pulmonary Vasculature Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1877 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass, E. Takimoto, T. Nagayama, and H. C. Champion Phosphodiesterase regulation of nitric oxide signaling Cardiovasc Res, July 15, 2007; 75(2): 303 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Friebe, E. Mergia, O. Dangel, A. Lange, and D. Koesling Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase PNAS, May 1, 2007; 104(18): 7699 - 7704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Bubb, M. L. Cock, M. J. Black, M. Dodic, W.-M. Boon, H. C. Parkington, R. Harding, and M. Tare Intrauterine growth restriction delays cardiomyocyte maturation and alters coronary artery function in the fetal sheep J. Physiol., February 1, 2007; 578(3): 871 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. V. Fedorova, N. I. Agalakova, C. H. Morrell, E. G. Lakatta, and A. Y. Bagrov ANP Differentially Modulates Marinobufagenin-Induced Sodium Pump Inhibition in Kidney and Aorta Hypertension, December 1, 2006; 48(6): 1160 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Blount, R. Zoraghi, H. Ke, E. P. Bessay, J. D. Corbin, and S. H. Francis A 46-Amino Acid Segment in Phosphodiesterase-5 GAF-B Domain Provides for High Vardenafil Potency over Sildenafil and Tadalafil and Is Involved in Phosphodiesterase-5 Dimerization Mol. Pharmacol., November 1, 2006; 70(5): 1822 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Oliver, V. P. Melville, and D. J. Webb Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension Hypertension, October 1, 2006; 48(4): 622 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Bender and J. A. Beavo Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use Pharmacol. Rev., September 1, 2006; 58(3): 488 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Piggott, K. A. Hassell, Z. Berkova, A. P. Morris, M. Silberbach, and T. C. Rich Natriuretic Peptides and Nitric Oxide Stimulate cGMP Synthesis in Different Cellular Compartments J. Gen. Physiol., June 26, 2006; 128(1): 3 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Williams, C. R. White, M. M. Chang, E. R. Injeti, L. Zhang, and W. J. Pearce Chronic hypoxic decreases in soluble guanylate cyclase protein and enzyme activity are age dependent in fetal and adult ovine carotid arteries J Appl Physiol, June 1, 2006; 100(6): 1857 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R.V. Castro, I. Verde, D. M.F. Cooper, and R. Fischmeister Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes Circulation, May 9, 2006; 113(18): 2221 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Raizen, K. M. Cullison, A. I. Pack, and M. V. Sundaram A Novel Gain-of-Function Mutant of the Cyclic GMP-Dependent Protein Kinase egl-4 Affects Multiple Physiological Processes in Caenorhabditis elegans Genetics, May 1, 2006; 173(1): 177 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. V. Evgenov, C. J. Busch, N. V. Evgenov, R. Liu, B. Petersen, G. E. Falkowski, B. Petho, A. Vas, K. D. Bloch, W. M. Zapol, et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L723 - L729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jaillard, B. Larrue, P. Deruelle, A. Delelis, T. Rakza, G. Butrous, and L. Storme Effects of Phosphodiesterase 5 Inhibitor on Pulmonary Vascular Reactivity in the Fetal Lamb. Ann. Thorac. Surg., March 1, 2006; 81(3): 935 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Lobato, T. Beaver, J. Muehlschlegel, D. S. Kirby, C. Klodell, and A. Sidi Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension Br. J. Anaesth., March 1, 2006; 96(3): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Potter, S. Abbey-Hosch, and D. M. Dickey Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions Endocr. Rev., February 1, 2006; 27(1): 47 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Teixeira, F. B. M. Priviero, and R. C. Webb Differential Effects of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 654 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hofmann, R. Feil, T. Kleppisch, and J. Schlossmann Function of cGMP-Dependent Protein Kinases as Revealed by Gene Deletion Physiol Rev, January 1, 2006; 86(1): 1 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tahseldar-Roumieh, R. Ghali-Ghoul, C. Lugnier, and R. Sabra Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H481 - H488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Belmonte, C. Ticconi, S. Dolci, M. Giorgi, A. Zicari, A. Lenzi, E. A. Jannini, and E. Piccione Regulation of Phosphodiesterase 5 Expression and Activity in Human Pregnant and Non-pregnant Myometrial Cells by Human Chorionic Gonadotropin Reproductive Sciences, December 1, 2005; 12(8): 570 - 577. [Abstract] [PDF]
|
|
|
|
|
|
R. C. Dukarm, R. H. Steinhorn, J. A. Russell, S. Lakshminrusimha, D. Swartz, and J. J. Cummings Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs J Appl Physiol, December 1, 2005; 99(6): 2331 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Gore and R Silver Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis Ann Rheum Dis, September 1, 2005; 64(9): 1387 - 1387. [Full Text] [PDF]
|
|
|
|
|
|
J. Yang, J. W. Clark, R. M. Bryan, and C. S. Robertson Mathematical modeling of the nitric oxide/cGMP pathway in the vascular smooth muscle cell Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H886 - H897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. D'Andrea, Y. Qiu, D. Haynes-Johnson, S. Bhattacharjee, P. Kraft, and S. Lundeen Expression of PDE11A in Normal and Malignant Human Tissues J. Histochem. Cytochem., July 1, 2005; 53(7): 895 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wharton, J. W. Strange, G. M. O. Moller, E. J. Growcott, X. Ren, A. P. Franklyn, S. C. Phillips, and M. R. Wilkins Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 105 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Wilkins, G. A. Paul, J. W. Strange, N. Tunariu, W. Gin-Sing, W. A. Banya, M. A. Westwood, A. Stefanidis, L. L. Ng, D. J. Pennell, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1292 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Anctil, I. Poulain, and C. Pelletier Nitric oxide modulates peristaltic muscle activity associated with fluid circulation in the sea pansy Renilla koellikeri J. Exp. Biol., May 15, 2005; 208(10): 2005 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wagner, M. Russwurm, R. Jager, A. Friebe, and D. Koesling Dimerization of Nitric Oxide-sensitive Guanylyl Cyclase Requires the {alpha}1 N Terminus J. Biol. Chem., May 6, 2005; 280(18): 17687 - 17693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Zieman, V. Melenovsky, and D. A. Kass Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 932 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. O. Nikolaev, S. Gambaryan, S. Engelhardt, U. Walter, and M. J. Lohse Real-time Monitoring of the PDE2 Activity of Live Cells: HORMONE-STIMULATED cAMP HYDROLYSIS IS FASTER THAN HORMONE-STIMULATED cAMP SYNTHESIS J. Biol. Chem., January 21, 2005; 280(3): 1716 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Takimoto, H. C. Champion, D. Belardi, J. Moslehi, M. Mongillo, E. Mergia, D. C. Montrose, T. Isoda, K. Aufiero, M. Zaccolo, et al. cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism Circ. Res., January 7, 2005; 96(1): 100 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-L. Xu, H. M. Wolde, V. Gavrilyuk, V. L. Baughman, and D. A. Pelligrino cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2501 - H2509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Devynck, A. Simon, M.-G. Pernollet, G. Chironi, J. Gariepy, F. Rendu, and J. Levenson Plasma cGMP and Large Artery Remodeling in Asymptomatic Men Hypertension, December 1, 2004; 44(6): 919 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meurer, S. Pioch, K. Wagner, W. Muller-Esterl, and S. Gross AGAP1, a Novel Binding Partner of Nitric Oxide-sensitive Guanylyl Cyclase J. Biol. Chem., November 19, 2004; 279(47): 49346 - 49354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ichinose, J. D. Roberts Jr, and W. M. Zapol Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator: Current Uses and Therapeutic Potential Circulation, June 29, 2004; 109(25): 3106 - 3111. [Full Text] [PDF]
|
|
|
|
|
|
R. Feil, S. M. Lohmann, H. de Jonge, U. Walter, and F. Hofmann Cyclic GMP-Dependent Protein Kinases and the Cardiovascular System: Insights From Genetically Modified Mice Circ. Res., November 14, 2003; 93(10): 907 - 916. [Abstract] [Full Text] [PDF]
|
|